Health
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer – Medical Xpress
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung…
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory. Researchers from The University of Texas MD Anderson Cancer Center published the study results today in Nature Medicine.
The NEOSTAR…
-
General16 hours agoUber driver says rideshare app tells workers to flout road rules as bill introduced
-
General12 hours agoPerson in potentially life-threatening condition after wall collapses in Brisbane’s West End
-
Noosa News8 hours agoPolice appealing for information about ‘suspicious’ Brisbane charity fire that killed 44-year-old man
-
General8 hours agoFugitive prisoner who evaded police for months charged after dramatic Alice Springs arrest